Mirae Asset Global Investments Co., Ltd. Arcutis Biotherapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $28 Billion
- Q2 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,605 shares of ARQT stock, worth $96,152. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,605
Previous 4,010
14.84%
Holding current value
$96,152
Previous $62,000
3.23%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ARQT
# of Institutions
246Shares Held
130MCall Options Held
407KPut Options Held
216K-
Suvretta Capital Management, LLC New York, NY11.5MShares$241 Million5.56% of portfolio
-
Jennison Associates LLC11.1MShares$232 Million0.09% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$224 Million3.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$206 Million7.3% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$180 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.26B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...